428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Interleukin 18 (Recombinant Human Mutein Clone St-067) Triple-Negative Breast Carcinoma	Simcha IL-18, Inc.	P1/2	CC (45)
Ivermectin Triple-Negative Breast Carcinoma	Yuan Yuan	P1/2	CC (45)
mr001 bispecific antibody for Triple-Negative Breast Carcinoma	Shenzhen Majory Biotechnology Co., Ltd.	P1/2	CC (45)
Nogapendekin Alfa Inbakicept Triple-Negative Breast Carcinoma	ImmunityBio, Inc.	P2	CC (45)
Numarzu-001 Triple-Negative Breast Carcinoma	Fundacio Clinic Barcelona	P1/2	CC (45)
Azenosertib Triple-Negative Breast Carcinoma	Filipa Lynce, MD	P1	CC (44)
Seviteronel Triple-Negative Breast Carcinoma	St Vincent's Hospital, Sydney	P1/2	CC (44)
[177lu]lu-dpi-4452 Triple-Negative Breast Carcinoma	ITM Oncologics GmbH	P1/2	CC (43)
18f-flt Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
[68ga]ga-dpi-4452 Triple-Negative Breast Carcinoma	ITM Oncologics GmbH	P1/2	CC (43)
Avzo-021 Triple-Negative Breast Carcinoma	Avenzo Therapeutics, Inc.	P1/2	CC (43)
Berzosertib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Copanlisib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Elimusertib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Felmetatug Vedotin Triple-Negative Breast Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
Fermented Wheat Germ Extract Triple-Negative Breast Carcinoma	University of California, Davis	P1	CC (43)
Fluzone Quadrivalent Triple-Negative Breast Carcinoma	Rush University Medical Center	P1	CC (43)
Gtaexs617 Triple-Negative Breast Carcinoma	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1/2	CC (43)
(-)-Hydroxyurea Methylacylfulvene Triple-Negative Breast Carcinoma	Lantern Pharma Inc.	P1/2	CC (43)
kfa115 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
LY3143921 Triple-Negative Breast Carcinoma	Cancer Research UK	P1	CC (43)
ly4170156 Triple-Negative Breast Carcinoma	Eli Lilly and Company	P1	CC (43)
Modified Vaccinia Virus Ankara Vaccine Expressing P53 Triple-Negative Breast Carcinoma	City of Hope Medical Center	P1	CC (43)
pf-08046054 Triple-Negative Breast Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
Pirfenidone Triple-Negative Breast Carcinoma	Harbin Medical University	P1/2	CC (43)
Polo-Like Kinase 1 Inhibitor Nms-1286937 Triple-Negative Breast Carcinoma	Antonio Giordano, MD	P1/2	CC (43)
Ribociclib Triple-Negative Breast Carcinoma	Avenzo Therapeutics, Inc.	P1/2	CC (43)
Rtx-224 Triple-Negative Breast Carcinoma	Rubius Therapeutics	P1/2	CC (43)
The-0504 Triple-Negative Breast Carcinoma	Thena Biotech S.r.l.	P1	CC (43)
Tolinapant Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Tub-030 Triple-Negative Breast Carcinoma	Tubulis GmbH	P1/2	CC (43)
Vidutolimod Triple-Negative Breast Carcinoma	Regeneron Pharmaceuticals	P2	CC (43)
Xmab808 Triple-Negative Breast Carcinoma	Xencor, Inc.	P1	CC (42)
a2b395 Triple-Negative Breast Carcinoma	A2 Biotherapeutics Inc.	P1/2	CC (41)
Adg 106 Triple-Negative Breast Carcinoma	National University Hospital, Singapore	P1/2	CC (41)
an0025 Triple-Negative Breast Carcinoma	Adlai Nortye Biopharma Co., Ltd.	P1	CC (41)
Apl-5125 Triple-Negative Breast Carcinoma	Apollo Therapeutics Ltd	P1/2	CC (41)
azd6750 Triple-Negative Breast Carcinoma	AstraZeneca	P1/2	CC (41)
Blex 404 Triple-Negative Breast Carcinoma	BioLite, Inc.	P1/2	CC (41)
Cedazuridine Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
CF33-expressing hNIS Triple-Negative Breast Carcinoma	City of Hope Medical Center	P1	CC (41)
exs74539 Triple-Negative Breast Carcinoma	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1	CC (41)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-3101 (89.9%) -(Ighd) -Ighj401 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg101 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (85.3%)-Igkj201 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa Triple-Negative Breast Carcinoma	Cancer Research UK	P1/2	CC (41)
gen1107 Triple-Negative Breast Carcinoma	Genmab	P1/2	CC (41)
Giloralimab Triple-Negative Breast Carcinoma	AbbVie	P1	CC (41)
Hafnium Oxide Triple-Negative Breast Carcinoma	Nanobiotix	P1	CC (41)
Hbi 0201-Eso Tcrt Triple-Negative Breast Carcinoma	Hadassah Medical Organization	P1/2	CC (41)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-2301 (81.6%) -(Ighd) -Ighj302 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg103V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-3301 (87.8%) -Igkj401 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Triple-Negative Breast Carcinoma	Genentech, Inc.	P1	CC (41)
hs-10502 Triple-Negative Breast Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	CC (41)
hs-20089 Triple-Negative Breast Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	CC (41)

Showing 251 to 300 of 428 assets

PreviousPage 6 of 9Next